On Thursday Morning, July 11, Alnylam (ALNY) shared some very positive data from an ongoing Phase 1 trial of ALN-TTRsc. The market loved the data enough to send its shares soaring 15% before the market opened, where they stayed until the close. After a day to digest the news, the market drove shares even higher, then back to Earth. On Thursday, July 18, shares of Alnylam closed at $42.87, still about 14% higher than its closing price of $37.6 on Wednesday, July 10.
I have to admit I found the initial response to Alnylam's Phase 1 data baffling. Isis Pharmaceuticals (ISIS) is also working on a transthyretin-mediated amyloidosis [ATTR] therapy, and it is much...
Only subscribers can access this article, which is part of the PRO research library covering 3,604 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: